Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr;8(7):472. doi: 10.21037/atm.2020.03.129

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2020 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

The expression of akt-mTOR protein (A,B,C,D) and inhibitory cytokines (E,F) in different groups. (A,B) The p-akt was decreased significantly in group A compared with other groups, **P<0.01; (C,D) the mTOR and p-mTOR all decreased significantly in group A compared with other groups, **P<0.01. (E) Histogram of IL-10 between different groups analyzed with ANOVA, obviously down-regulation in group A, *P<0.05; (F) histogram of TGF-β1 between different groups analyzed with ANOVA, remarkably down-regulation in group A, *P<0.05. group A, SRL-based therapy/SRL⁺; group B, SRL/RAPA; group C, Thymalfasin/Zadaxin; group D, Huaier extract/PS-T; group E, HCC model; group F, Blank/Control.